Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T L Timme

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Cancer Gene Therapy|February 18, 2006
Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancerK Naruishi, T L Timme, N Kusaka, et al.
Clinical & Experimental Metastasis|July 27, 2001
Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progressionM R Shaker, G Yang, T L Timme, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 1998
Elevated expression of caveolin is associated with prostate and breast cancerG Yang, L D Truong, T L Timme, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccinesG W Hull, M A Mccurdy, Y Nasu, et al.
Gene Therapy|October 7, 2006
Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancerT Fujita, T L Timme, K Tabata, et al.
Human Gene Therapy|November 1, 2001
Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapyB J Miles, M Shalev, E Aguilar-Cordova, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Cancer Gene Therapy|February 18, 2006
Adenoviral vector-mediated RTVP-1 gene-modified tumor cell-based vaccine suppresses the development of experimental prostate cancerK Naruishi, T L Timme, N Kusaka, et al.
Clinical & Experimental Metastasis|July 27, 2001
Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progressionM R Shaker, G Yang, T L Timme, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 1998
Elevated expression of caveolin is associated with prostate and breast cancerG Yang, L D Truong, T L Timme, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccinesG W Hull, M A Mccurdy, Y Nasu, et al.
Gene Therapy|October 7, 2006
Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancerT Fujita, T L Timme, K Tabata, et al.
Human Gene Therapy|November 1, 2001
Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapyB J Miles, M Shalev, E Aguilar-Cordova, et al.
Pageof 6